Metastatic Pancreatic Adenocarcinoma
Conditions
Keywords
BRCAness status, KRAS somatic status
Brief summary
MAZEPPA is open-label, phase II study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in Pancreatic ductal adenocarcinoma (PDAC) patients with disease controlled after 4 months of mFOLFIRINOX chemotherapy as following: Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile and with KRAS mutation randomization between durvalumab plus selumetinib Arm B, versus FOLFIRI Arm C.
Detailed description
Searching for efficient maintenance therapies in metastatic PDAC patients whose disease has been controlled using an induction chemotherapy is crucial for two main reasons: 1. Patients may stop IV toxic chemotherapy while their tumor remains under control. Although up to 70% of PDAC patients achieve tumor control when treated during induction with mFOLFIRINOX, toxicity of this regimen, particularly neuropathy and fatigue, remains a key concern. 2. Tumor control may be extended, which might improve quality of life (QoL) and survival. Patients are included in MAZEPPA study based on the genetic profile of their tumor. * If a BRCA gene mutation is present in the tumor, treatment with the drug olaparib will be proposed (arm A), regardless of the status of the other genes analyzed. * In the absence of a mutation in the BRCA gene and in the presence of a mutation in the KRAS gene, a treatment combining immunotherapy and targeted therapy (durvalumab and selumetinib - Arm B) or chemotherapy by FOLFIRI (arm C) will be proposed.
Interventions
DRUGArm A - Olaparib
300 mg orally twice daily, for a total daily dose of 600mg Study treatment can be dose-reduced to : First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued.
DRUGARM B - durvalumab plus selumetinib
Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily Study treatment can be dose-reduced to : Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily
DRUGARM C FOLFIRI
FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
Sponsors
AstraZeneca
GERCOR - Multidisciplinary Oncology Cooperative Group
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile and with KRAS mutation randomization between durvalumab plus selumetinib Arm B, versus FOLFIRI Arm C.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed and dated informed consent, 2. Age ≥18 years 3. Body weight \>30 kg, 4. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up, 5. Life expectancy of at least 4 months, 6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, 7. Pathologically confirmed pancreatic adenocarcinoma with distant metastases (stage IV disease), 8. No prior therapy for metastatic disease other than mFOLFIRINOX (in case of previous adjuvant therapy, the interval between the end of adjuvant chemotherapy and relapse must be \>6 months), 9. Stability or tumor response (Response evaluation criteria in solid tumors \[RECIST\] 1.1) after 4 months of mFOLFIRINOX (8 cycles) for metastatic disease, 10. Have tissue from archival tissue sample from surgery or biopsy identified and confirmed as available for study 11. Availability of tumor somatic genetic analyses data, performed during the first 4 months of mFOLFIRINOX (specific informed consent), 12. In case of germinal BRCA gene mutation identified before inclusion the patient can be included until olaparib receives a marketing authorization for the treatment indication of the patients in the study and the treatment is available in the retail pharmacy; it will be prescribed according to the summary product characteristics (SmPC), 13. At least one measurable or evaluable lesion as assessed by CT-scan or MRI according to RECIST 1.1 and feasibility of repeated radiological assessments, 14. Normal organ and bone marrow function prior to administration of study treatment as defined below: * Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days, * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, * Platelet count ≥ 100 x 109/L, * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x institutional ULN unless liver metastases are present in which case ≤ 5x ULN, * Creatinine clearance (CrCl) ≥ 50 mL/min estimated using the Cockcroft-Gault equation, Estimated CrCl =(140-age \[years\]) x weight (kg) (x F)a serum creatinine (mg/dL) x 72 a F=0.85 for females and F=1 for males. 15. Absence of known dihydropyrimidine dehydrogenase (DPD) deficiency, 16. Female patients must be surgically sterile, or be post-menopausal, or have negative serum pregnancy test if pre-menopausal at inclusion and must commit to using reliable and appropriate methods of contraception during the study and during at least 6 months after the end of studytreatment (when applicable). Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \< 50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). * Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). All female patients with reproductive potential must have a negative pregnancy test (beta human chorionic gonadotropin \[β-HCG\]) within 72 hours prior to starting the protocol treatment. Breastfeeding is not allowed. Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least 6 months after the end of the study treatment. Men and women with childhood potential are required to use adequate birth control during the study, 17. Registration in a national health care system (PUMa; Couverture Maladie Universelle included).
Exclusion criteria
1. Histology other than PDAC 2. Toxicities after mFOLFIRINOX treatment not resolved to ≥ grade 1 prior to maintenance treatment, except for oxaliplatin induced neuropathy, alopecia, or grade ≥ 2 are permitted 3. Patients with known brain metastases at inclusion, 4. Enrollment in another therapeutic trial 5. Evidence of interstitial lung disease, any active non-infectious pneumonitis, or known active infection including active tuberculosis 6. Hepatitis B virus (HBV; known positive HBV surface antigen (HbsAg) result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV ½ antibodies). 7. Active uncontrolled infection, current unstable, or uncompensated respiratory or cardiac conditions, or active digestive hemorrhages less than 3 months, 8. Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study, 9. Live vaccine administration within 30 days prior to the first dose of study treatment, 10. Treatment with any other investigational medicinal product within 28 days prior to study entry, 11. Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), and stage 1, grade 1 endometrial carcinoma, 12. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months prior to starting treatment, prior or current cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent, 13. Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the Investigator or patients with congenital long QT syndrome. Mean corrected QT interval (QTc) for heart rate using the QTcF formula ≥ must be \<470 ms, 14. Pregnancy/lactation, 15. Uncontrolled massive pleural effusion or massive ascites, 16. Tutelage or guardianship. Arm A: Specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ARM A - Progression free survival (PFS) | at 4 months | PFS rate at 4 months is defined by the number of patients alive at 4 months from inclusion without PD divided by the total number of patients evaluable at 4 months (dead during 4 months or alive at 4 months with a progressive status available). |
| ARM B/ C - PFS | Assessed up to 36 months | PFS is defined as time from randomization into arm B/C to the date of first documented PD RECIST 1.1 and/or iRECIST for arm B and PD RECIST1.1 for arm C or death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | Assessed up to 36 months | OS is the time between the date of inclusion into Arm A or Arms B/C and death |
| Disease control rate (DCR) | Measured at 16 weeks of maintenance therapy. | DCR is the percentage of patients who achieve CR, PR, or SD to study treatment (according to RECIST 1.1). |
| Time to HRQoL score definitive deterioration (TUDD) | At baseline, at every 2 months during treatment, and at the end of treatment visit. Assessed up to 36 months | TUDD is defined as the time interval between inclusion into Arm A and randomization into Arms B/C and the first occurrence of a decrease in QLQ-C30 score for dimension ⩾5 points compared to baseline HRQoL score without any further improvement in QoL score ⩾5 points or any further available QoL data. |
| Number of participants with treatment-related adverse events | Assessed up to 36 months | All grade and severe toxicities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
| Overall response rate (ORR) | Assessed up to 36 months | ORR is the number of patients with a best overall response of CR or PR divided by the number of all treated (at least 1 dose of study treatment) patients. |
Countries
France
Outcome results
None listed